NCT00116506View on ClinicalTrials.gov

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Colorectal CancerNeoplasm Metastasis
Interventions
DRUG

erlotinib

DRUG

FOLFOX

DRUG

bevacizumab

Trial Locations (3)

02114

Massachusett General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Sanofi-Synthelabo

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER